Formycon Reveals Keytruda Biosimilar In The Works
A Formulation Patent Is Pending While Manufacturing Capacity Has Been Secured
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
You may also be interested in...
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.
With global sales north of $15bn in the first nine months of the year, Merck is desperate to shield its Keytruda for as long as possible, including with a potential subcutaneous formulation.
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.